Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 9/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | EDNRA | P25101 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | HBB | P68871 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.40 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2346356 | 0.87 | PNP (0.51) | PNPHSD17B10USP2TSHREDNRA | |
| SCHEMBL10421279 | 0.87 | PNP (0.54) | PNPHSD17B10KDM4EMEN1ALDH1A1 | |
| SCHEMBL1767745 | 0.82 | PNP (0.56) | PNPHSD17B10KDM4EMEN1ALDH1A1 | |
| SCHEMBL8397615 | 0.82 | PNP (0.54) | PNP | |
| SCHEMBL350396 | 0.80 | PNP (0.61) | PNPHSD17B10KDM4EMEN1ALDH1A1 | |
| SCHEMBL14079841 | 0.80 | PNP (0.66) | PNPHSD17B10KDM4EMEN1ALDH1A1 | |
| SCHEMBL2343355 | 0.79 | PNP (0.59) | PNPHSD17B10KDM4EMEN1ALDH1A1 | |
| SCHEMBL4908015 | 0.79 | PNP (0.51) | PNPHSD17B10BLMKDM4EMEN1 | |
| SCHEMBL10711111 | 0.77 | PNP (0.51) | PNPHSD17B10USP2TSHREDNRA | |
| SCHEMBL9960811 | 0.76 | PNP (0.71) | PNPHSD17B10KDM4EMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 252 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260083840-A1 | METHODS FOR ABLATING MYELOID DERIVED SUPPRESSOR CELLS USING NEO-201 ANTIBODY | PREC BIOLOGICS INC (US) | 2026-03-26 | — | — | US | claimed |
| EP-4499710-A1 | METHODS FOR ABLATING MYELOID DERIVED SUPPRESSOR CELLS USING NEO-201 ANTIBODY | Precision Biologics, Inc. (US) | 2025-02-05 | — | — | EP | claimed |
| US-20240400714-A1 | METHODS AND COMPOSITIONS FOR TARGETING TREG CELLS | PREC BIOLOGICS INC (US) | 2024-12-05 | — | — | US | claimed |
| US-20240384003-A1 | METHODS AND COMPOSITIONS FOR TREATING HEMATOLOGICAL MALIGNANCIES | PREC BIOLOGICS INC (US) | 2024-11-21 | — | — | US | claimed |
| CN-112041343-B | Methods and compositions for targeting Treg cells | 精密生物制品股份有限公司 | 2024-08-30 | — | — | CN | claimed |
| CN-118234748-A | Methods and compositions for treating hematological malignancies | 精密生物制品股份有限公司 | 2024-06-21 | — | — | CN | claimed |
| EP-4352103-A2 | METHODS AND COMPOSITIONS FOR TREATING HEMATOLOGICAL MALIGNANCIES | Precision Biologics, Inc. (US) | 2024-04-17 | — | — | EP | claimed |
| WO-2023225608-A1 | METHODS FOR ABLATING MYELOID DERIVED SUPPRESSOR CELLS USING NEO-201 ANTIBODY | PRECISION BIOLOGICS, INC. (US) | 2023-11-23 | — | — | WO | claimed |
| WO-2022246066-A2 | METHODS AND COMPOSITIONS FOR TREATING HEMATOLOGICAL MALIGNANCIES | PRECISION BIOLOGICS, INC. (US) | 2022-11-24 | — | — | WO | claimed |
| US-20210002383-A1 | METHODS AND COMPOSITIONS FOR TARGETING TREG CELLS | PREC BIOLOGICS INC (US) | 2021-01-07 | — | — | US | claimed |
| US-20140219957-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF IMMUNE DISORDERS | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2014-08-07 | — | — | US | claimed |
| WO-2013185055-A1 | METHODS AND COMPOSITIONS FOR THE INHIBITION OF PIN1 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2013-12-12 | — | — | WO | claimed |
| WO-2012162698-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF IMMUNE DISORDERS | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2012-11-29 | — | — | WO | claimed |
| US-20100144618-A1 | Compositions containing an intestinal trefoil peptide and a mucoadhesive | PODOLSKY DANIEL K | 2010-06-10 | — | — | US | claimed |
| US-20060189526-A1 | COMPOSITIONS CONTAINING AN INTESTINAL TREFOIL PEPTIDE AND A MUCOADHESIVE | THE GENERAL HOSPITAL CORPORATION | 2006-08-24 | — | — | US | claimed |
| US-RE38341-E1 | Method for electrokinetic delivery of medicaments | BIOPHORETIC THERAPEUTIC SYSTEMS, LLC | 2003-12-09 | — | — | US | claimed |
| US-5879323-A | IONOPHORETIC TRANSDERMAL DELIVERY OF A 2-HYDROXYETHOXY(METHYL)GUANINE INTO TISSUES OVERLYING MUCOCUTANEOUS HERPES TYPE I AND TYPE II INFECTIONS | THE APS ORGANIZATION, LLP (US) | 1999-03-09 | — | — | US | claimed |
| EP-0531452-A4 | SYNTHESIS OF GLYCEROL DI- AND TRIPHOSPHATE DERIVATIVES | — | 1993-06-09 | — | — | EP | claimed |
| EP-0531452-A1 | SYNTHESIS OF GLYCEROL DI- AND TRIPHOSPHATE DERIVATIVES | NeXstar Pharmaceuticals, Inc. (US) | 1993-03-17 | — | — | EP | claimed |
| WO-1991018914-A1 | SYNTHESIS OF GLYCEROL DI- AND TRIPHOSPHATE DERIVATIVES | VICAL, INC. (US) | 1991-12-12 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260083840-A1 | METHODS FOR ABLATING MYELOID DERIVED SUPPRESSOR CELLS USING NEO-201 ANTIBODY | CD47, SIGLEC9, LGALS1 | PNP 1734/4885HSD17B10 4695/4885USP2 1667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.